Consumers are inundated with false information circulating online about GLP-1 medicines, which causes confusion and can lead to potentially serious health problems resulting from dosing errors and adverse reactions to ingredients in compounded GLP-1 products.
The post It’s Time to Put Guardrails on GLP-1 Compounding appeared first on MedCity News.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
